GlassScriptPhysician profile
Imran Jawaid
NPI 1992152961
$1,888.71
in general payments reported to CMS, 2019-2025
28 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $133 · 2022: $299 · 2023: $380 · 2024: $651 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.53 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $375.83 | 2022-2025 | Cimzia, Bimzelx |
| Amgen INC. | $230.38 | 2022-2025 | Krystexxa, Tepezza, Otezla |
| Calliditas Therapeutics US INC. | $181.78 | 2023-2024 | Tarpeyo |
| Novo Nordisk INC | $155.32 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Akebia Therapeutics INC | $118.49 | 2021 | |
| Radius Health, INC. | $84.57 | 2022-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $71.78 | 2022-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $64.71 | 2022-2025 | Terlivaz |
| Averitas Pharma INC. | $63.06 | 2024-2025 | Qutenza |
| Antares Pharma, INC. | $62.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $59.01 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $44.28 | 2022-2023 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $43.55 | 2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $34.86 | 2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $33.77 | 2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.43 | 2023-2025 | Ofev |
| Alexion Pharmaceuticals, INC. | $31.46 | 2024 | Strensiq |
| Lilly USA, LLC | $30.70 | 2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $23.84 | 2024 | |
| Janssen Biotech, INC. | $20.48 | 2022 | |
| Abbvie INC. | $20.04 | 2025 | |
| Sumitomo Pharma America, INC. | $16.76 | 2023 | Gemtesa |
| Glaxosmithkline, LLC. | $15.71 | 2022 | |
| Dexcom, INC. | $15.62 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $14.87 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.39 | 2022 | |
| Boston Scientific Corporation | $14.08 | 2023 | Watchman Access System |
| Insulet Corporation | $13.98 | 2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Jawaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.